Skip to content

Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke

A Randomized Trial on Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke (HOPE Study)

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04892511
Acronym
HOPE
Enrollment
814
Registered
2021-05-19
Start date
2021-06-01
Completion date
2024-09-30
Last updated
2023-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Brief summary

Mechanical thrombectomy is a very effective treatment in patients who have suffered an acute ischemic stroke associated with intracranial large vessel occlusion. However, less than half of the patients achieve functional independence despite treatment. The optimization of blood pressure after mechanical thrombectomy based on the degree of recanalization achieved at the end of the procedure could improve the perfusion of the ischemic brain tissue thanks to the improvement of blood circulation provided by collateral circulation. For this, authorized hypotensive or hypertensive drugs will be used. Moreover, this individualized treatment would allow to decrease reperfusion injury and therefore decrease the risk of intracerebral bleeding complications and cerebral edema. Therefore, we designed a clinical trial in which the standard management of blood pressure after mechanical thrombectomy will be compared with a specific protocol in which blood pressure targets are applied according to the degree of recanalization obtained during the thrombectomy procedure. The beneficial effect and risk reduction of this treatment will translate into a better short and long-term outcome

Interventions

OTHERAdjusted medication

In patients randomized to perfusion optimization, medication will be adjusted to maintain blood pressure according to the degree of recanalization: * Patients with TICI 2b: systolic blood pressure 140-160 mmHg. * Patients with TICI 2c-3: systolic blood pressure \<140 mmHg. Hypotensive drugs will be used when necessary. Intravenous labetalol is the treatment of choice, administered as a bolus or intravenous infusion. Alternative: urapidil (bolus or continuous infusion pump). If both drugs cannot be used or are insufficient, sodium nitroprusside can be used. Hypertensive drugs for TICI2b patients whose target pressure is 140-160mmHg and are below this range. Initially, a bolus of physiological saline or 100cc Plasmalyte® will be administered. If this treatment is not effective enough (blood pressure measurements persist \<140 mmHg), intravenous phenylephrine will be administered.

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with acute ischemic stroke and large intracranial vessel occlusion within 24 hours after the onset of symptoms in whom mechanical thrombectomy has been performed. * Successful recanalization, defined as a TICI score of 2b, 2c, or 3. * Previous score on the modified Rankin scale (mRS) of 0, 1, or 2. * The patient or her legal representative gives informed written or verbal consent

Exclusion criteria

* ASPECTS score \<6 * Vertebral, basilar, A2, P2 and M3-4 occlusion * History of intracerebral hemorrhage * Pregnant or breastfeeding patient * Patient with congestive heart failure or recent/unstable coronary artery disease (\<3 months) * Dissection of aorta, cervical or cerebral or unruptured aortic / cerebral aneurysm or known arteriovenous malformation * Any bleeding visible on baseline CT * History of ventricular arrhythmias * Use of MAO inhibitors * Inclusion in other clinical trials.

Design outcomes

Primary

MeasureTime frameDescription
Modified Rankin scale value3 monthsState of functional independence, measured with the modified Rankin scale at 3 months (+/- 14 days).

Secondary

MeasureTime frameDescription
Mortality3 monthsMortality from any cause at 3 months post-thrombectomy
Intracranial hemorrhagic complication24 hoursRate of any intracranial hemorrhagic complication in the first 24 hours after the procedure.
NIHSS score24 hours
Infarct size in the 24-hour post-thrombectomy CT.24 hoursInfarct size in the 24-hour post-thrombectomy CT.
Infarct size in the 72-hour post-thrombectomy CT.72 hoursInfarct size in the 72-hour post-thrombectomy CT.
Cerebral edema24 hoursVolume of cerebral edema at 24 hours in the post-thrombectomy CT scan.

Countries

Spain

Contacts

Primary ContactJoan Martí-Fàbregas, PhD, MD
jmarti@santpau.cat0034 93 5537636
Backup ContactPol Camps-Renom, PhD, MD
pcamps@santpau.cat0034 935565986

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 9, 2026